Increased frequency of CD56Bright NK-cells, CD3 -CD16+CD56- NK-cells and activated CD4 +T-cells or B-cells in parallel with CD4+CDC25 High T-cells control potentially viremia in blood donors with HCV

Journal of Medical Virology

Volumn 81, Issue 1, 2009, Pages 49-59

  Zarife, Maria Alice Sant'anna ^a,b   Reis, Eliana Almeida Gomes ^a   Carmo, Theomira Mauadie Azevedo ^a   Lopes, Gisele Barreto ^a   Brandão, Emilia Carolina Malafaia ^a   Silva, Helder Reis ^a   Santana, Nelma ^c   Martins Filho, Olindo Assis ^a   Reis, Mitermayer Galvão ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Laboratório Central de Saúde Pública Professor Gonçalo Moniz LACEN BA   (Brazil)

^c Fundacao de Hematologia e Hemoterapia do Estado da Bahia HEMOBA   (Brazil)

Author keywords

Activated T and B cells; Blood donors; CD4 +CD25high; HCV; NK and NKT cells

Indexed keywords

CD24 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; COCAINE; INTERLEUKIN 2 RECEPTOR ALPHA; MARKER; RNA; LEUKOCYTE ANTIGEN;

ACUPUNCTURE; ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD AND HEMOPOIETIC SYSTEM; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; BODY PIERCING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; COCAINE DEPENDENCE; DIALYSIS; DRUG USE; ELECTRIC POTENTIAL; FEMALE; FLOW CYTOMETRY; HEMATOLOGY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYRINGE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TATTOO; VIREMIA; VIRUS LOAD; CHEMISTRY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED;

HEPATITIS C VIRUS;

ADULT; ANTIGENS, CD; B-LYMPHOCYTES; BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA;

EID: 58149217118     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21340     Document Type: Article

References (50)

1. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. 2004. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78:2454-2459.
2. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V. 2004. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 113:963-972.
3. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. 2001. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 167:1245-1253.
4. Bendelac A, Rivera MN, Park SH, Roark JH. 1997. Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu Rev Immunol 15:535-562.
5. Bertoletti A, Ferrari C. 2003. Kinetics of the immune response during HBV and HCV infection. Hepatology 38:4-13.
6. Bluestone JA, Abbas AK. 2003. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253-257.
7. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, Blum HE, von Weizsacker F, Thimme R. 2005. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79:7860-7867.
8. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. 2001. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33:267-276.
9. Chevaliez S, Pawlotsky JM. 2007. Hepatitis C virus: Virology, diagnosis and management of antiviral therapy. World J Gastroenterol 13:2461-2466.
10. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. 2001. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146-3151.
11. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. 2000. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355.
12. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. 2000. The liver as a site of T-cell apoptosis: Graveyard, or killing field? Immunol Rev 174:47-62.
13. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EA, Seed CR, Krusius T, Lin C, Medgyesi GA, Kiyokawa H, Olim G, Duraisamy G, Cuypers T, Saeed AA, Teo D, Conradie J, Kew MC, Lin M, Nuchaprayoon C, Ndimbie OK, Yap PL. 1995. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 50 non-coding region. J Gen Virol 76:1197-1204.
14. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C, Greenberg PD, Stromnes IM, Iwashiro M, Sakaguchi S, Evans LH, Peterson KE, Yang G, Hasenkrug KJ. 2004. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20:293-303.
15. Emoto M, Kaufmann SH. 2003. Liver NKT cells: An account of heterogeneity. Trends Immunol 24:364-369.
16. Global Burden of Hepatitis C Working Group. 2004. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44:20-29.
17. Godfrey DI, Kronenberg M. 2004. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379-1388.
18. Golden-Mason L, Rosen HR. 2006. Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? Liver Transpl 12:363-372.
19. Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O'Farrelly C, Doherty DG. 2008. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121-1128.
20. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P. 2001. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75:5550-5558.
21. Guglietta S, Garbuglia AR, Pacciani V, Scotta C, Perrone MP, Laurenti L, Spada E, Mele A, Capobianchi MR, Taliani G, Folgori A, Vitelli A, Ruggeri L, Nicosia A, Piccolella E, Del Porto P. 2005. Positive selection of cytotoxic Tlymphocyte escape variants during acute hepatitis C virus infection. Eur J Immunol 35:2627-2637.
22. Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN. 1994. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity 1:741-749.
23. Janeway CA, Jr., 2001. How the immune system protects the host from infection. Microbes Infect 3:1167-1171.
24. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. 2002. Infectious tolerance: Human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 196:255-260.
25. Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA, Lanier LL, Liu YJ. 2001. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J Exp Med 193:1221-1226.
26. Kanto T, Hayashi N. 2007. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol Res 37:S319-S326.
27. Kantzanou M, Lucas M, Barnes E, Komatsu H, Dusheiko G, Ward S, Harcourt G, Klenerman P. 2003. Viral escape and T cell exhaustion in hepatitis C virus infection analysed using class I peptide tetramers. Immunol Lett 85:165-171.
28. Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. 2002. Immunomodulatory effects of the liver: Deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol 169:2407-2413.
29. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD. 1992. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149:3339-3344.
30. Krajden M. 2000. Hepatitis C virus diagnosis and testing. Can J Public Health 91:34-39.
31. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. 2007. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: Evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109:845-846.
32. Large MK, Kittlesen DJ, Hahn YS. 1999. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence. J Immunol 162:931-938.
33. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. 2005. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79:6023-6034.
34. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, Cerny A, Phillips R, Ferrari C, Pape GR, Klenerman P. 2000a. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30:2479-2487.
35. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. 2000b. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191:1499-1512.
36. Mittrucker HW, Kaufmann SH. 2004. Mini-review: Regulatory T cells and infection: Suppression revisited. Eur J Immunol 34:306-312.
37. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI. 2001. Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells. Blood 98:2736-2744.
38. O'Garra A, Vieira P. 2004. Regulatory T cells and mechanisms of immune system control. Nat Med 10:801-805.
39. Poynard T, Yuen MF, Ratziu V, Lai CL. 2003. Viral hepatitis C. Lancet 362:2095-2100.
40. Shevach EM. 2002. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2:389-400.
41. Sondergaard SR, Ullum H, Pedersen BK. 2000. Proliferative and cytotoxic capabilities of CD16+CD56- and CD16+/-CD56+ natural killer cells. Apmis 108:831-837.
42. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99:15669-15674.
43. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. 2003. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38:1437-1448.
44. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395-1406.
45. Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. 2003. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77:862-870.
46. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. 1997. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology 25:449-458.
47. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, Zachoval R, Pape GR, Diepolder HM. 2003. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 37:1189-1198.
48. Vigouroux S, Yvon E, Biagi E, Brenner MK. 2004. Antigen-induced regulatory T cells. Blood 104:26-33.
49. Vitelli-Avelar DM, Sathler-Avelar R, Dias JC, Pascoal VP, Teixeira-Carvalho A, Lage PS, Eloi-Santos SM, Correa-Oliveira R, Martins-Filho OA. 2005. Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16-CD56+ natural killer T cells and CD4+CD25 High regulatory T lymphocytes. Scand J Immunol 62:297-308.
50. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. 2002. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169:3447-3458.